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Summary
New therapies, including the anti-cytotoxic T lymphocyte antigen (CTLA)-4 
antibody, ipilimumab, is approved for metastatic melanoma. Prognostic 
biomarkers need to be identified, because the treatment has serious side 
effects. Serum samples were obtained before and during treatment from 
56 patients with metastatic or unresectable malignant melanoma, receiving 
treatment with ipilimumab in a national Phase IV study (NCT0268196). 
Expression of a panel of 17 inflammatory-related markers reflecting dif-
ferent pathways including extracellular matrix remodeling and fibrosis, 
vascular inflammation and monocyte/macrophage activation were meas-
ured at baseline and the second and/or third course of treatment with 
ipilimumab. Six candidate proteins [endostatin, osteoprotegerin (OPG), 
C-reactive protein (CRP), pulmonary and activation-regulated chemokine 
(PARC), growth differentiation factor 15 (GDF15) and galectin-3 binding-
protein (Gal3BP)] were persistently higher in non-survivors. In particular, 
high Gal3BP and endostatin levels were also independently associated with 
poor 2-year survival after adjusting for lactate dehydrogenase, M-stage 
and number of organs affected. A 1  standard deviation increase in en-
dostatin gave 1·74 times [95% confidence interval (CI)  =  1·10–2·78, 
P  =  0·019] and for Gal3BP 1·52 times (95% CI  =  1·01–2·29, P  =  0·047) 
higher risk of death in the adjusted model. Endostatin and Gal3BP may 
represent prognostic biomarkers for patients on ipilimumab treatment in 
metastatic melanoma and should be further evaluated. Owing to the non-
placebo design, we could only relate our findings to prognosis during 
ipilimumab treatment.
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Introduction
Metastatic melanoma (MM) often affects younger people 
and is the most devastating form of cancer regarding 
life-years lost. Dacarbazine (DTIC) has traditionally been 
the standard therapeutic drug for patients with MM, 
but the response rates are low (approximately 10%), 
and the effect not sustained [1]. In Europe, until 2011 
no new drugs had been approved for the treatment of 
MM for more than 30 years. Since then new therapeutic 
approaches have been authorized, including immuno-
therapy with ipilimumab (anti-CTLA-4 antibody), as 
well as nivolumab and pembrolizumab [programmed 
cell death 1 (PD)-1 inhibitors] and the combination of 
ipilimumab and nivolumab, resulting in improved overall 
survival [2–8]. At present, the first line of systemic 
immunotherapy for MM includes ipilimumab/nivolumab 
combination or nivolumab or pembrolizumab alone. 
Second-line treatment depends on the choice in the 
first line, but includes ipilimumab, and PD-1 inhibitors 
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only or in combination with other new immune check-
point inhibitors in clinical trials. At present, however, 
immunotherapies in MM lack prognostic biomarkers. 
As these therapeutic options also have serious side effects, 
markers could help to select patients that will be in 
particular benefit of such therapy.
Overcoming tumor immune tolerance can be induced 
by monoclonal antibodies (mAbs) blocking negative 
signaling receptors, such as cytotoxic T lymphocyte 
antigen 4 (CTLA-4), which is a central regulation mecha-
nism for T cell activation. Ipilimumab is a human 
CTLA-4 mAb that blocks the interaction with its ligands 
CD80/CD86, and can lead to long-lasting anti-tumor 
effects and disease control. In MM, approximately 20% 
of patients experience long-term survival after treatment 
with ipilimumab [4,9], but 20–27% of patients treated 
develop serious side effects (grades 3–4) [10]. Access 
to biomarkers defining patients likely to respond and 
survive has been long awaited [11].
The development and progression of MM are charac-
terized by chronic inflammation [12,13] which has been 
recognized as a driving force for both epidermal cell 
transformation as well as malignant progression. Thus, a 
wide range of inflammatory and related mediators, includ-
ing cytokines, chemokines, regulators of the extracellular 
matrix (ECM), reactive oxygen species and angiogenic 
factors, are present in the tumor microenvironment. Such 
factors may be derived from infiltrating inflammatory cells 
and/or from the tumor cells or interactions between these 
cells, and may influence the rate of tumor progression 
and the outcome of cancer treatment [14]. These inflam-
matory mediators may be quantified in the circulation 
and utilized as biomarkers [11,15–17]. Thus, whereas MM 
in itself is associated with enhanced inflammation, immu-
notherapy such as ipilimumab will further activate certain 
inflammatory pathways. To characterize the inflammatory 
phenotype in MM as well as how this phenotype changes 
during successful ipilimumab therapy may be of major 
importance to selected patients who will benefit from such 
treatment.
Based on these issues, we examined markers reflecting 
different inflammatory pathways that could give novel 
information on prognosis during immunotherapy (i.e. 
ipilimumab) in MM. We selected markers on the basis 
that they reflected activation of pathways that are relevant 
for melanoma progression [18] as well as the effects of 
ipilimumab [19]. Against this background we examined 
general downstream markers of inflammation [i.e. 
C-reactive protein (CRP), soluble tumor necrosis factor 
receptor type 1 (sTNFR1)], markers of endothelial cell 
activation and vascular inflammation [i.e. pentraxin 3 
(PTX3), osteoprotegerin (OPG), von Willebrand factor 
(vWF), the chemokine CXCL16 and the notch ligand 
delta-like 1 (DLL1)], angiogenetic factors [i.e. Axl, endothe-
lial cell protein C receptor (ePCR) and endostatin], markers 
related to fibrosis and extracellular matrix (ECM) remod-
eling [i.e. growth differentiation factor 15 (GDF-15), 
galectin 3 binding protein (Gal3BP), cathepsin S (CatS/
CD147)] and markers reflecting monocyte/macrophage 
activation [the chemokine CCL18 and the soluble (s) 
markers sCD163 and activated leukocyte cell adhesion 
molecule (ALCAM)/sCD166]) at three time-points in 
melanoma patients treated with ipilimumab and evaluated 
their association with 2  years’ survival. As this were non-
randomized real-world data, the identified markers could 
only be assigned prognostic value on ipilimumab treatment 




From January 2014 to March 2015, 69 patients with unre-
sectable or metastatic malignant melanoma were included 
and started treatment with ipilimumab as part of a national 
Phase IV study (NCT0268196/EudraCT2013-002408-15) 
at the Department of Oncology, Oslo University Hospital, 
The Norwegian Radium Hospital. The patients received 
treatment with up to four doses of ipilimumab 3  mg/kg 
intravenously every third week. Six patients had  ≤  two 
doses of ipilimumab due to very rapid disease progres-
sion, eight patients had three courses due to high-grade 
side effects, and the remainder had all four doses as 
planned. A total number of 56 patients from whom fresh-
frozen serum samples were obtained at baseline (before 
the start of treatment), week 4 (before the second treat-
ment) and/or week 7 (before the third treatment) were 
included in this substudy. The 13 patients who were not 
reported were due to screening failure (four patients) and 
lack of blood tests taken (nine patients). Thus, none of 
the patients who were not reported showed rapid dete-
rioration during follow-up. The patients started therapy 
on week 1 and were followed-up every third week during 
treatment. They had the first computerized tomography 
(CT) scan for evaluation at week  12, and the next scan 
at week 16 to evaluate pseudoprogression. Further regular 
visits and CT scans were at week  24 and every third 
month after that for 3  years or until progression. The 
study was approved by the regional ethics committee and 
conducted by the Declaration of Helsinki. All patients 
gave written informed consent to participate in the study.
Blood sampling and biochemical analyses
Peripheral venous blood was drawn into pyrogen-free 
tubes without any additives. After coagulation at room 
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temperature, tubes were centrifuged at 1500 g for 10 min, 
and serum was stored at –80°C in multiple aliquots. Serum 
levels of CRP (Cat. no. DY1707), PTX3 (Cat. no. DY1826), 
sTNFR1 (Cat. no. DY225), OPG (Cat. no. DY805), DLL1 
(Cat. no. DY1818), CXCL16 (Cat. no. DY1164), Axl (Cat. 
no. DY154), ePCR (Cat. no. DY2245), endostatin (Cat. 
no. DY1098), GDF-15 (Cat. no. DY957), CatS (Cat. no. 
DY1183), CD147 (Cat. no. DY972), CCL18 (Cat. no. 
DY394), Gal3BP (Cat. no. DY2226), sCD163 (Cat. no. 
DY1607) and sCD166 (Cat. no. DY656) were measured 
in duplicate by enzyme-linked immunosorbent assay with 
antibodies obtained from R&D Systems (Minneapolis, MN, 
USA) in a 384 format using a combination of a CyBi 
SELMA (CyBio, Jena, Germany), EL406 washer/dispenser 
(Biotek, Winooski, VT, USA) and Synergy H2 microplate 
reader (Biotek). vWF was measured by the same method 
with antibodies obtained from DakoCytomation (Glostrup, 
Denmark). The intra- and interindividual coefficients of 
variation were  <10%.
Statistical analysis
As the inflammatory markers were skewed, data were 
analyzed using the Mann–Whitney U-test and χ2 correla-
tion. Receiver operating characteristic (ROC) curves of 
inflammatory markers at baseline were created, and the 
area under the curve (AUC) was used to evaluate the 
prognostic effect of each parameter. Where appropriate, 
Kaplan–Meier curved on dichotomized levels, multivari-
able logistic regression analysis and Cox proportional 
hazards regression [adjusted for lactate dehydrogenase 
(LDH) levels, M stage and number of organs affected] 
were performed in order to assess the relationship between 
inflammatory markers [log-transformed with hazard ratios 
expressed per standard deviation (s.d.) change], clinical 
parameters and the outcome of survival after 2  years. 
Survival at 2  years was defined from trial inclusion. Two-
sided P-values of  <0·05 were considered significant. spss 
version 23 software (IBM, Armonk, NY, USA) was used 
for all statistical analyses.
Results
Patient characteristics
Table 1 presents the baseline characteristics of the MM 
patient population according to survival status. Twenty-
three (41%) of the patients were alive and thirty-three 
(59%) were dead 2  years after inclusion in the Phase IV 
study. All non-survivors died from disease progression 
of melanoma. As expected, non-survivors had a more 
advanced disease stage and higher LDH serum levels than 
survivors. Twelve of the survivors and thirteen of the 
non-survivors had a BRAF V600 mutated tumor. Most 
patients had one or no systemic treatment before they 
were included in the study.
In contrast to what has been reported by others [20–23], 
we found no correlation between peripheral blood bio-
markers such as absolute neutrophil count (ANC), absolute 
eosinophil count (AEC), absolute lymphocyte count (ALC) 
or increase in AEC or ALC and outcome of ipilimumab 
treatment.
Patients included in this study had a broad spectrum 
and grade of different immune-related side effects (irAE). 
However, the number of patients in our cohort was some-
what low (n  =  56), and we therefore did not group the 
irAE according to grade or type of irAE in statistical 
analyses. When we included all irAE (grades 1–4) regularly 
registered during the treatment visits in the IPI4 study, 
we found no association between any immune-related side 
effect and 2  years of survival.




Yes (alive) No (dead)
23 (41) 33 (59)
Gender
Men 11 (20) 22 (39)
Women 12 (21) 11 (20)
Age, years, Median (range) 60 (27–83) 67 (38–84)
M stage M1a/b 9 (38) 4 (14)
M1c 14 (62) 29 (86)*
Organs involved ≤ 2 16 (29) 13 (23)
>2 7 (12) 20 (36)
BRAF v600 Mutation, No 8 (14) 17 (30)
Yes 12 (21) 13 (23)
Unknown 3 (5) 3 (5)
LDH, normal 19 (34) 14 (25)
>ULN† 4 (7) 19 (34)**
Number of treatments 
before inclusion, 0
11 (20) 18 (32)
1 9 (16) 13 (23)
2 2 (4) 1 (1·7)
3 1 (1·7) 1 (1·7)
ANC# 4·7 (1·7) 4·8 (1·4)
AEC# 0·1 (0·1) 0·1 (0·1)
ALC# 1·6 (0·5) 1·4 (0·6)
Increase AEC 13 (57) 18 (55)
Increase ALC 17 (74) 16 (49)
irAE 8 (35) 15 (46)
Data are shown as number of patients (%) unless otherwise 
indicated.
†ULN = upper limit of normal, #mean (standard deviation). *P < 0·05; 
**P < 0·01 versus survivors.
ANC = absolute neutrophil count (109/l); AEC = absolute eosinophil 
count (109/l); ALC  =  absolute lymphocyte count (109/l); irAE  =  im-
mune-related adverse event; LDH  =  lactate dehydrogenase (U/l); 
M stage = metastatic stage (AJCC cancer staging manual).
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Biomarkers during treatment
Median and interquartile levels of the examined markers 
before treatment (i.e. baseline), at second treatment (i.e. 
4  weeks) and at third treatment (i.e. 7  weeks) with ipili-
mumab are presented in Table 2. Several of the markers 
demonstrated higher levels in serum from non-survivors 
compared to survivors at several time-points, i.e. CRP, 
sTNFR1, PTX3, OPG, CXCL16, Axl, endostatin, GDF15, 
Gal3BP, CatS, CCL18/PARC and sCD163. Of these, CRP, 
endostatin, GDF15, OPG, PARC and Gal3BP were con-
sistently elevated in non-survivors at all time-points and 
were therefore selected for further analyses.
Baseline levels of inflammatory markers in relation to 
disease severity
Of the six selected inflammatory markers, several were 
associated with different measures of disease severity, 
as shown in Table 3. First, significantly higher levels 
of GDF15, endostatin, PARC and CRP were observed 
in patients with more organs affected. Secondly, GDF15, 
Gal3BP and CRP were significantly higher in patients 
with stage M1c, reflecting a higher tumor burden. 
Similarly, OPG, GDF15, PARC and CRP levels were 
significantly higher in those with higher LDH as a marker 
of tissue damage, above the upper limit of normal 
individuals.
Predictors of outcome
We next evaluated the accuracy of the selected markers 
in predicting disease outcome using ROC analysis. As 
shown in Fig. 1a, all the selected markers at baseline 
gave good discrimination between survivors and non-
survivors, with AUC between 0·70 and 0·76. Further, 
all markers, except Gal3BP, displayed a symmetrical area 
indicating that median levels could be a reasonable cut-
off. Kaplan–Meier survival curves for all-cause mortality, 
using the median to dichotomize the data, confirmed 
that higher levels of each marker were associated with 
poor prognosis. We next evaluated the prognostic value 
of the selected markers in multivariable Cox-regression 
models. Figure 2a shows the univariate and multivari-
able analysis of clinical markers, indicating that these 
markers were significantly associated with all-cause 
mortality, and also when put together in a multivariable 
model. These markers of disease severity were used in 
subsequent adjustment strategies. Figure 2b shows the 
univariate and multivariable analysis (i.e. adjusted for 
LDH levels, M-stage and number of organs affected) 
for each of the suggested biomarkers. All markers were 
associated with all-cause mortality in univariate analysis, 
with hazard ratios (HR) between 1·7 and 2·2. The asso-
ciation between survival and GDF15, OPG and PARC 
were markedly attenuated by multivariable adjustment 
and were no longer significantly associated with death. 
Endostatin and Gal3BP were also modified by adjust-
ment but remained significantly associated with all-cause 
death. Figure 2c shows a Cox regression model with a 
stepwise selection of the best clinical and biochemical 
variables and indicates that endostatin and LDH are 
the strongest predictors, followed by M-stage.
Discussion
Ipilimumab has improved survival in subgroups of patients 
with MM, but no biomarker is currently available for 
predicting treatment benefit. The present study was initi-
ated to evaluate if biomarkers reflecting inflammation, 
vascular inflammation, angiogenesis and ECM remodeling 
could predict prognosis in patients treated with ipilimumab. 
Several markers reflecting different pathways correlated 
with indices of disease severity were consistently elevated 
in non-survivors after initiation of treatment. In particular, 
high levels of Gal3BP and endostatin were also indepen-
dently associated with poor survival in adjusted analysis, 
and deserve further attention as possible prognostic bio-
markers in this population.
Whereas ipilimumab enhances the immune response 
against tumor, persistent low-grade local and systematic 
immune response and inflammation could also promote 
tumor progression and death of patients with MM [24,25]. 
Several studies have revealed an association between leu-
kocyte counts, conventional markers such as CRP and 
LDH and clinical outcome in MM [20–23,25–31]. The 
present study supports and extends these findings by 
showing that biomarkers that reflect a range of inflam-
matory-related pathways, including vascular inflammation, 
ECM remodeling/fibrosis and angiogenesis, correlate with 
different indices of disease severity, and are consistently 
up-regulated in non-survivors after initiation of ipili-
mumab. Thus, low or normal levels of OPG, GDF15, 
endostatin, PARC, Gal3BP and CRP in MM patients have 
the potential to identify patients who may benefit from 
such therapy. Indeed, comparing these biomarkers in 
multivariable analysis revealed that two of these markers, 
i.e. endostatin and Gal3BP, were independently associated 
with poor prognosis, suggesting that these markers could 
reflect distinct processes related to MM progression that 
is not necessarily reversed by ipilimumab therapy.
Endostatin is a 20-kDa C-terminal fragment from type 
XVIII collagen, generally found in epithelial and endothe-
lial vascular basement membranes, and is an endogenous 
inhibitor of angiogenesis [32,33]. Endostatin blocks the 
proliferation and organization of endothelial cells into 
new blood vessels and inhibits angiogenesis and growth 
of both primary tumors and secondary metastasis 
M. Nyakas et al.
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 197: 74–82
78
[34–38]. Interestingly, endostatin seems to be predomi-
nantly linked to angiogenesis arriving from pathogenic 
sources such as tumors, while processes such as wound 
healing are not affected [39], and endostatin has been 
suggested as adjuvant therapy in various malignancies. 
High expression of endostatin in tumor tissue may also 
indicate poor prognosis, probably reflecting substantial 
tumor burden and active stromal remodeling [40]. Thus, 
the association between high endostatin levels, the num-
ber of organs affected and poor outcome in our study 
could potentially reflect an enhanced compensatory 
response to limit angiogenesis as well as ECM remod-
eling. Our finding is supported by previous studies 
demonstrating that high circulating endostatin levels are 
associated with poor outcome or an aggressive phenotype 
in a variety of malignancies [40–44]. It is also possible 
that endostatin could counteract the effect of ipilimumab 
by attenuating the infiltration of activated T cells into 
the tumor, but this hypothesis needs to be proved in 
future studies.
Table 2. Serum levels (quartiles) of biomarkers before and during treatment with ipilimumab stratified survival status
Survival Baseline Week 4 Week 7
Inflammation in general
CRP (μg/ml) Alive 0·8 (0·2, 2·3) 1·0 (0·5, 3·5) 1·5 (0·6, 3·5)
Dead 2·8 (1·4, 5·4)** 4·8 (2·4, 6·4)** 3·8 (2·5, 7·0)**
sTNF-R1 (ng/ml) Alive 2·2 (1·8, 2·6) 2·3 (2·0, 3·1) 2·5 (2·0, 2·8)
Dead 2·2 (1·9, 3·3) 3·2 (2·6, 4·7)** 3·1 (2·5, 5·3)**
Vascular inflammation
PTX3 (ng/ml) Alive 1·1 (0·6, 1·7) 1·2 (0·6, 1·9) 1·3 (0·8, 1·9)
Dead 1·9 (1·0, 2·5) 2·3 (1·6, 3·6)** 2·2 (1·4, 4·1)**
OPG (ng/ml) Alive 3·5 (3·0, 4·5) 3·7 (2·9, 4·8) 3·8 (3·4, 5·0)
Dead 5·1 (3·8, 5·6)** 5·5 (4·0, 6·5)* 6·2 (4·2, 6·8)**
vWF (AU) Alive 58 (48, 71) 61 (51, 87) 64 (37, 92)
Dead 68 (51, 87) 73 (59, 113) 65 (33, 126)
CXCL16 (ng/ml) Alive 2·3 (2·1, 2·7) 2·4 (2·1, 2·8) 2·1 (2·0, 2·6)
Dead 2·7 (2·3, 3·3) 2·6 (2·2, 3·2) 2·7 (2·3, 3·1)**
DLL1 (ng/ml) Alive 13·7 (11·3, 16·4) 14·8 (12·9, 20·0) 14·4 (12·1, 15·8)
Dead 13·6 (12·1, 15·9) 15·1(13·5, 17·8) 17·0 (12·9, 18·9)
Angiogenesis
Axl (ng/ml) Alive 5·2 (4·1, 5·6) 5·2 (4·3, 5·7) 5·3 (4·5, 6·1)
Dead 5·3 (4·6, 6·4) 5·9 (5·4, 6·5)** 6·0 (5·4, 8·6)**
ePCR (ng/ml) Alive 33 (29, 43) 32 (27, 39) 33 (27, 38)
Dead 36 (28, 41) 35 (28, 41) 37 (32, 43)
Endostatin (ng/ml) Alive 134 (113, 154) 132 (114·5, 147·5) 133 (115, 162)
Dead 158 (137, 189)* 170·5 (155, 202)* 181 (148, 221)**
ECM/fibrosis
GDF15 (ng/ml) Alive 0·4 (0·2, 0·7) 0·4 (0·3, 0·8) 0·4 (0·3, 0·8)
Dead 0·8 (0·4, 1·4)** 0·7 (0·5, 2·0)** 0·8 (0·5, 1·9)**
Gal3BP/sCD166 (μg/ml) Alive 1·2 (0·8, 2·0) 1·3 (0·7, 2·4) 1·0 (0·9, 2·0)
Dead 2·0 (1·7, 3·1)** 2·4 (1·7, 4·1)** 2·7 (1·9, 3·4)*
CatS (ng/ml) Alive 53 (47, 61) 56 (50, 61) 55 (50, 59)
Dead 55 (51, 60) 56 (38, 62) 60 (54, 67)**
CD147 (ng/ml) Alive 9·1 (7·3, 10·2) 9·4 (7·4, 11·1) 8·9 (7·4, 10·3)
Dead 8·7 (7·5, 10·0) 9·9 (8·2, 11·7) 10·1 (8·1, 12·4)
Monocyte/macrophage 
activation
CCL18/PARC (ng/ml) Alive 65 (55, 88) 79 (58, 102) 78 (68, 96)
Dead 102 (78, 115)* 103 (78, 134)** 115 (85, 155)**
sCD163 (ng/ml) Alive 421 (317, 690) 516 (353, 645) 562 (317, 699)
Dead 650 (494, 831) 824 (595, 1066)** 865 (557, 1145)**
Alcam/sCD166 (ng/ml) Alive 102 (92, 121) 107 (92, 112) 105 (97, 121)
Dead 101 (84, 115) 107 (89, 121) 102 (89, 131)
*P < 0·05; **P < 0·01 comparing non-survivors and survivors.
CRP = C-reactive protein; sTNF-R1 = soluble tumor necrosis factor receptors; PTX3 = pentraxin-related protein/TNF-inducible gene 14 protein 
(TSG-14); OPG = osteoprotegerin; vWF = Von Willebrand factor; ePCR = endothelial cell protein C receptor; CXCL = chemokine ligand; DLL1 = delta-
like protein 1; ECM = extracellular matrix; GDF15 = growth differentiation factor 15; Gal3BP = galectin-3 binding-protein/CYT-MAA/K90/Mac-2BP; 
CatS = cathepsin S; PARC = pulmonary and activation-regulated chemokine.
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Galectins are a family of beta-galactoside-binding proteins 
implicated in modulating cell–cell and cell–matrix interac-
tions, angiogenesis and apoptosis [45]. Galectin-3-binding 
protein is a glycoprotein expressed in normal cells, but 
elevated circulating levels have been demonstrated in mul-
tiple cancers [46–52] including melanoma [53]. The role 
of Gal3BP in cancer prognosis seems equivocal with both 
negative and positive influences on the prognosis of vari-
ous cancers, but high levels are mainly associated with 
shorter survival, disease progression [54,55] and reduced 
response to chemotherapy. Our finding of consistently 
increased Gal3BP following immunotherapy supports a 
previous study showing an association between high levels 
and clinical outcome in melanoma patients [45,54], but 
so far there are no data on Gal3BP or endostatin as bio-
markers of ipilimumab therapy. Mechanisms underlying 
over-expression of Gal3BP in cancer is not fully understood, 
but its association with multiple forms of cancer could be 
related to the multidomain nature of the protein and abil-
ity to bind different ligands in different tumor tissues.
Table 3. Serum levels quartiles of selected markers at start of treatment in relation to disease severity
Organs involved M stage LDH
OPG (ng/ml) ≤2 4·0 (3·4–4·6) M1a/b 3·7 (2·9–4·7) Norm 4·0 (3·4–4·6)
>2 4·9 (4·2–5·7) M1c 4·6 (4·1–5·2) >ULN 5·0 (4·3–6·0)*
GDF15 (ng/ml) ≤2 0·5 (0·3–0·7) M1a/b 0·4 (0·2–0·7) Norm 0·4 (0·3–0·7)
>2 1·0 (0·7–1·5)* M1c 0·8 (0·6–1·1)* >ULN 1·1 (0·7–1·8)**
Endostatin (ng/ml) ≤2 139 (127–151) M1a/b 135 (118–155) Norm 142 (130–154)
>2 162 (148–178)* M1c 154 (143–166) >ULN 161 (146–178)
PARC (ng/ml) ≤2 75 (66–86) M1a/b 74 (60–92) Norm 76 (67–85)
>2 99 (87–113)** M1c 90 (80–100) >ULN 103 (90–119)**
Gal3BP (µg/ml) ≤2 1·7 (1·3–2·2) M1a/b 1·1 (0·8–1·6) Norm 1·5 (1·2–1·9)
>2 1·8 (1·4–2·3) M1c 1·9 (1·6–2·3)* >ULN 2·1 (1·6–2·7)
CRP (µg/ml) ≤2 1·1 (0·7–1·7) M1a/b 0·8 (0·4–1·5) Norm 1·1 (0·7–1·7)
>2 2·1 (1·3–3·4)* M1c 1·8 (1·3–2·6)* >ULN 2·3 (1·4–3·8)*
Data are given as back-transformed estimated marginal means adjusted for age and sex. > ULN = above upper level of normal; LDH = lactate dehy-
drogenase; M stage = metastatic stage (AJCC cancer staging manual); OPG = osteoprotegerin; GDF15 = growth differentiation factor 15; PARC = pul-
monary and activation-regulated chemokine; Gal3BP = galectin-3 binding-protein/CYT-MAA/K90/Mac-2BP; CRP = C-reactive protein.
*P < 0·05; **P < 0·01 comparing non-survivors and survivors.
Fig. 1. Survival analysis of inflammatory biomarkers during ipilimumab therapy. (a) Receiver operating curves (ROC) and diagnostic accuracy for 
all-cause mortality. (b) Kaplan–Meier curves for all-cause mortality by dichotomized levels of inflammatory markers.
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As this was not a placebo-controlled trial, it is hard 
to conclude if the association of high levels of endostatin 
and Gal3BP was a marker of treatment efficiency or related 
to disease progression independently of therapy. At pre-
sent, we can only suggest that high levels of these markers 
reflect disease progression during ipilimumab therapy. 
However, the mechanisms for this association seem to 
differ between the two markers. Thus, as endostatin has 
been shown to have anti-angiogenetic properties with 
potential attenuating effects on carcinogenesis, the high 
levels may reflect counteracting mechanisms in a tumor 
with a large pro-angiogenetic potential and therefore poor 
prognosis. Conversely, Gal3BP may reflect activation of 
pathways that promote maladaptive ECM remodeling 
which could enhance tumor progression. Indeed, a recent 
study in melanoma shows that the combination of ipili-
mumab with the vascular endothelial growth factor 
(VEGF)-A blocking antibody bevacizumab induced 
increased antibody response to galectin-3, and this response 
was associated with improved prognosis [56]. No such 
antibody response was seen during PD-1 inhibition.
To the best of our knowledge, endostatin or GAL3BP 
have not been reported as markers for treatment efficacy 
during immunotherapy in melanoma or other cancers. 
However, a galectin 3 inhibitor, in combination with 
ipilimumab or PD-1 inhibition, is being currently evalu-
ated for the treatment of patients with metastatic melanoma 
[57] underscoring that galectin 3 or its marker Gal3BP 
(as well as endostatin) could be part of a panel of bio-
markers that predicts the outcome for immunotherapy 
in melanoma. Our data suggest endostatin and Gal3BP 
as potential prognostic biomarkers for ipilimumab in MM. 
The study does not provide mechanistic insight into the 
relationship between biomarkers and induced responses, 
but it is tempting to speculate that the correlation with 
disease severity and consistent up-regulation of multiple 
inflammatory-related markers in non-survivors could 
reflect that these patients have progressed too far to 
respond to ipilimumab. Analysis of pretreatment blood 
samples could enable the identification of possible bio-
markers that could help in making treatment decisions 
in patients with MM. However, the number of included 
patients is small, and the results need to be confirmed 
in a larger study. Moreover, short-term observation, as 
in the present study (2  years), will ‘select’ for biomarkers 
that predict short-term progression rather than a favorable 
clinical outcome. Accordingly, larger studies with long-
term follow-up are needed to evaluate these molecules 
as potential biomarkers for long-term survival following 
ipilimumab therapy. The strength is, however, that this 
is a prospective study and the data are derived from a 
‘real-world’ patient cohort, and the selected candidates 
(i.e. endostatin and Gal3BP) should be further investigated 
in MM during various forms of therapeutic approaches.
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